Trial
NCT05204160
Pembrolizumab as Salvage Therapy for the Treatment of Multiple Myeloma in Patients Progressing on CAR-T Cell Therapy
Phase IIWITHDRAWNOPERATIONALConfidence: HIGH
Sponsor
Emory University
Collaborators
Merck Sharp & Dohme LLC; National Cancer Institute (NCI)
Condition
Plasma Cell Myeloma
Intervention
Pembrolizumab
Why stopped
slow accrual
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-07-03